A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer

Takefumi Komiya*, Regan M. Memmott, Gideon M. Blumenthal, Wendy Bernstein, Marc S. Ballas, Roopa De Chowdhury, Guinevere Chun, Cody J. Peer, William D. Figg, David J. Liewehr, Seth M. Steinberg, Giuseppe Giaccone, Eva Szabo, Shigeru Kawabata, Junji Tsurutani, Arun Rajan, Phillip A. Dennis

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Background: Single-agent pemetrexed is a treatment for recurrent non-squamous non-small cell lung cancer (NSCLC) that provides limited benefit. Preclinical studies showed promising synergistic effects when the mammalian target of rapamycin (mTOR) inhibitor sirolimus was added to pemetrexed. Methods: This was a single-institution phase I/II study of pemetrexed in combination with sirolimus. The primary endpoint for the phase I was to determine the maximum tolerated dose (MTD) and safety of the combination. The primary endpoint for the phase II portion was to determine the overall response rate at the MTD. Key eligibility criteria included recurrent, metastatic NSCLC, ECOG performance status of 0–2, and adequate organ function. Sirolimus was administered orally daily after an initial loading dose, and pemetrexed was given intravenously on day 1 of every 21-day cycle. Results: Forty-two patients with recurrent, metastatic NSCLC were enrolled, 22 in phase I and 20 in phase II. The MTD was pemetrexed 500 mg/m2 every 3 weeks, and sirolimus 10 mg on day 1, and 3 mg daily thereafter. Treatment-related adverse events (AEs) occurred in 38 (90.5%) patients. The most common grade 3–4 treatment-related AEs were lymphopenia (31%) and hypophosphatemia (19%). Two treatment-related deaths occurred due to febrile neutropenia and infection, respectively. Among 27 total patients treated at the MTD, 6 (22.2%) had a partial response (PR), 12 (44.4%) had stable disease (SD) and 5 (18.5%) had progressive disease. Median progression-free survival (PFS) was 18.4 weeks (95% CI: 7.0–29.4). Conclusions: The combination of pemetrexed and sirolimus is active in heavily-pretreated NSCLC.

Original languageEnglish
Pages (from-to)247-257
Number of pages11
JournalTranslational Lung Cancer Research
Issue number3
StatePublished - 1 Jun 2019
Externally publishedYes


  • Lung cancer
  • Pemetrexed
  • Phase I/II
  • Sirolimus
  • Thymidylate synthase (TS)


Dive into the research topics of 'A phase I/II study of pemetrexed with sirolimus in advanced, previously treated non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this